Artiva Biotherapeutics Inc ARTV

$4.19 -0.04 (-0.95%)

Valuation

Market cap
204,849,000
Revenue TTM
$0
Net income TTM
$-83,870,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,966,100
Avg volume
708,658
Day's range
$4.10 – $4.26
Shares out
48,890,000
Stochastic %K
7%
Beta
2.40
Analysts
Sell
Price target
$20.75

Price

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,...

Show more

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 267 4467
Website
https://www.artivabio.com
Address
5505 Morehouse Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

Merlintrader Oct 31, 6:41 PM
$ARTV closed the week at $4.19 (-31.9% w/w, -0.9% Friday), below the 50-day SMA ($8.11) and below the 200-day ($8.03). RSI14 20.6. Support $4.00, resistance $7.38 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies
InvestorNOR Oct 30, 3:00 PM
$CMMB $ARTV For those out of the loop: Artiva had to discontinue their entire pipeline after their RA drug failed Phase 2 and there was some deaths to patients. They are now without a pipeline, and is seeking strategic opportunities. They have unlike going concern crappy Scipher Medicine, cash. $300M which was collected to develop RA. And they have expertize in clinical trials, looking to cut 95% of their workforce. They had RA and SSc in the pipeline. That is now dead. nebokitug from Chemomab Therapeutics have Phase 2 for RA soon, they have IND for SSc clear, they have Phase 3 alignment with FDA for PSC, with Orphan status and Fast Track designation. Artiva have the expertise to run trials, they can develop nebokitug, without firing the people. They have $300M cash and can run PSC. Its a match made in heaven. Artiva wants a new IP, Chemomab wants a partner. Leerink have run outreach for Chemomab in 2024, they now run Artiva`s search for a partner. This is perfect.
2 replies
Snptrader Oct 30, 2:10 PM
$ARTV $CMMB 🤔
0 replies
Rolo2024 Oct 30, 2:04 AM
$ARTV Move your money to NRXP or SLS you will thank me later.
1 replies
Gravitationalsingularity Oct 29, 3:17 AM
$ARTV Anyone else notice those 2000 $5 18DEC26c sold for $0.3 at the open yesterday, because I did. It's trading way below market cap/cash on hand. They'll most likely do a reverse merger with GC to recoup the losses. Leerink Partners is going to find them a nice suitor, if it isn't going to be GC, but I don't think GC wants to let all of that IP and money get away. The stock is going to bounce back up above $5.
0 replies
toniotoro Oct 28, 6:29 PM
$ABUS as long as no one dies post phase 2 we should be good $ARTV
0 replies
DataClown Oct 28, 5:01 AM
$ARTV SEC 8-K filed 10/27: On 10/22, the board approved the full termination of its lead pipeline AlloNK. Reasons: long-term follow-up failed to confirm durable efficacy, plus a recent Grade 5 fatal adverse event. Roughly 94% of staff to be laid off, and the company is exploring strategic alternatives including sale or liquidation. It raised ~$300M back in May and was still advancing the RA Phase 3 program plus RMAT designation in August. Just ten weeks from a “transformative quarter” to liquidation. Both Needham and Wedbush cut their ratings to Hold on the day. Contrarian-bullish on the stub!!!
0 replies
Bbboston Oct 28, 1:46 AM
$ARTV Terrible news for the patients, and their families. Hopefully it’s something that can be sorted out and not a read block for the technology/approach.
0 replies